Biocompatible polymers and hydrogels and methods of use
Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. Applications for such biocompatible crosslinked polymers and their precursors include controlled delivery of drugs, prevention of post-operative adhesions, coating of medical devices such as vascular grafts, wound dressings and surgical sealants.
1. A method of making a biocompatible degradable hydrogel to treat a medical condition of a patient comprising:
identifying a medical condition for treatment by use of a hydrogel formed in situ in a patient and fully degradable in a patient in less than about 180 days; and
mixing a first precursor with a second precursor in situ in the patient to form the hydro gel for treatment of the medical condition,
with the first biocompatible synthetic hydrophilic polymer precursor having a water solubility of at least 1 gram per 100 milliliters and comprising at least two electrophilic functional groups; and the second biocompatible synthetic hydrophilic polymer precursor comprising at least two nucleophilic amine functional groups; and
wherein
(i) the first precursor is selected have only one or two chemically hydrolytically degradable ester bonds per every electrophilic functional group on the first precursor; and
(ii) the second precursor comprises at least three nucleophilic functional groups;
wherein the biodegradable groups of the hydrogel consist of the esters and the hydrogel as placed in situ in the patient is essentially fully degradable in a patient in less than about 180 days, and
wherein mixing the first and the second synthetic hydrophilic polymer precursors forms crosslinking covalent bonds that are reaction products of the electrophilic and the nucleophilic groups, wherein essentially every ester bond in the hydrogel is separated from other ester bonds in the hydrogel by at least three covalent bonds when the hydrogel is formed.
2. The method of claim 1 wherein the medical condition is adhesion prevention.
3. The method of claim 1 wherein the medical condition is tissue adhesion.
4. The method of claim 1 wherein the medical condition is drug delivery.
5. The method of claim 1 wherein the medical condition is wound covering.
6. The method of claim 1 wherein the medical condition is tissue sealing.
7. The method of claim 1 wherein the medical condition is tissue coating.
8. The method of claim 1 wherein the solids concentration of the hydrogel ranges from 8.5% to 20% w/w.
9. The method of claim 1 wherein the second precursor has a molecular weight of less than about 1000 Daltons.
10. The method of claim 1 wherein the first precursor comprises carboxymethyl-hydroxybutyrate-N-hydroxysuccinimidyl polyethylene glycol.
11. The method of claim 1 wherein the first precursor comprises succinimidyl glutarate.
12. The method of claim 1 wherein the electrophilic functional groups of the first precursor comprise n-hydroxysuccinimide ester.
13. The method of claim 1 wherein the electrophilic functional groups of the first precursor comprise a member of the group consisting of carbonyldiimidazole, sulfonyl chloride, aryl halides, sulfosuccinimide ester, epoxide, aldehyde, maleimides and imidoester.
14. The method of claim 1 wherein the second precursor consists essentially of a member of the group consisting of dilysine, trilysine, and tetralysine.
15. The method of claim 1 wherein at least one of the precursors is selected to further comprise a chemical group having the formula (CH 2 CH 2 O) n .
16. The method of claim 1 wherein the second precursor comprises a lysine.
17. The method of claim 1 wherein the hydrogel is essentially fully degradable in a patient in less than about 90 days.
18. The method of claim 1 wherein the hydrogel is essentially fully degradable in a patient in less than about 45 days.